ProQR to Start Clinical Trial of QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

May 12, 2017: By Jon Swedien

ProQRThe US FDA has given clearance to ProQR Therapeutics’ investigational new drug application for QR-110, a proposed treatment for Leber’s congenital amaurosis Type 10 (LCA 10) patients, the Netherlands company announced April 27.

ProQR said it intends to move forward with a Phase I/II open-label trial to assess the safety, tolerability, pharmacokinetics, and efficacy of multiple administrations of QR-110 in one eye of each patient. ProQR said the trial will include six adults and six children with LCA 10.

Topline results are expected in 2018.

QR-110 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of LCA 10, a mutation in the CEP290 gene. It is intended to be administered through intravitreal injections in the eye. QR-110 has been granted orphan drug designation in the US and European Union, the company said.

LCA 10 leads to progressive loss of vision, causing most patients to lose their sight in the first few years of life. There are no approved treatments or products in clinical development that treat the underlying cause of the disease, ProQR said.

ProQR is focused on RNA medicines for the treatment of severe genetic rare diseases such as LCA 10, cystic fibrosis, and dystrophic epidermolysis bullosa.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023